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Abstract
Purpose To assess the association between height and
risk of cancer and cancer death.
Methods The metabolic syndrome and cancer project is a
prospective pooled cohort study of 585,928 participants
from seven cohorts in Austria, Norway, and Sweden.
Hazard ratios (HRs) and 95 % confidence intervals (CIs)
for cancer incidence and death were estimated in height
categories and per 5-cm increment for each cancer site
using Cox proportional hazards model.
Results During a mean follow-up of 12.7 years (SD =
7.2), 38,862 participants were diagnosed with cancer and
13,547 participants died of cancer. Increased height (per
5-cm increment) was associated with an increased overall
cancer risk in women, HR 1.07 (95 % CI 1.06–1.09), and
in men, HR 1.04 (95 % CI 1.03–1.06). The highest HR was
seen for malignant melanoma in women, HR 1.17 (95 %
CI 1.11–1.24), and in men HR 1.12 (95 % CI 1.08–1.19).
Height was also associated with increased risk of cancer
death in women, HR 1.03 (95 % CI 1.01–1.16), and in
men, HR 1.03 (95 % CI 1.01–1.05). The highest HR was
observed for breast cancer death in postmenopausal women
([60 years), HR 1.10 (95 % CI 1.00–1.21), and death from
renal cell carcinoma in men, HR 1.18 (95 % CI 1.07–1.30).
All these associations were independent of body mass
index.
Conclusion Height was associated with risk of cancer and
cancer death indicating that factors related to height such
as hormonal and genetic factors stimulate both cancer
development and progression.
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Introduction
Adult height, determined by genetics and by nutrition in
childhood, has been associated with an increased risk of
some cancers such as cancer of the prostate [1], breast [2],
colorectum [3], ovary [4, 5], pancreas [6], kidney [7], testis
[8], endometrium [9], malignant melanoma [2, 10, 11], and
with lymphohematopoietic malignancies [12]. However,
there are only a few studies on all cancer sites, [2, 13–15]
and only one of these studies included men as well as
women [13]. Height has also been associated with an
increased risk of cancer death in contrast to the decreased
risk of total mortality and mortality from cardiovascular
diseases [16, 17]. To the best of our knowledge, no large
study to date has analyzed risk of cancer at all sites and
cancer death in the same study.
The aim of this prospective cohort study was to assess
the association between height and risk of cancer and
cancer death in a large prospective cohort in order to
provide precise estimates for risk of incident cancer and
cancer death overall and for specific cancer sites.
Materials and methods
Study population
This study was conducted within the metabolic syndrome
and cancer project (Me-Can), which consists of data from
health examinations performed in seven cohorts, which
have been described in detail previously [18]. In brief, the
Me-Can project includes cohorts from Norway; the Oslo
study I cohort (Oslo), Norwegian Counties Study (NCS),
Cohort of Norway (CONOR) and Age 40-programme (40-
y), from Sweden; Va¨sterbotten Intervention Project (VIP)
and Malmo¨ Preventive Project (MPP) from Austria;
Vorarlberg Health Monitoring and Prevention Program
(VHM&PP).
As part of the health examination data on height, weight
and smoking status were obtained. In all cohorts, weight
and height were measured with participants wearing light
indoor clothes and no shoes, and height was measured to
the nearest centimeter.
We only used data from first health examination [18],
and we excluded participants with height below 100 or
above 250 cm (1 participant), and participants with missing
value for height (3,412 participants). To account for age-
induced shrinkage, we further excluded participants with
health examination at age 80 years or above (4,551 par-
ticipants). Due to policy restrictions imposed by the Nor-
weigan Institute of Public Health that the proportion of
Norweigan participants in Me-Can studies could not
exceed 50 %, we randomly excluded participants from the
Norweigan sub-cohorts to the final dataset. The Me-Can
project was approved by research ethics review boards in
the respective countries.
End points
Cancer diagnoses were identified through linkages with the
National Cancer Registry in Sweden and Norway and
Vorarlberg State Cancer Registry in Austria [19–21]. The
International Classification of Diseases, seventh revision
(ICD-7) was used for identification of cancer cases. In
Norway and Sweden, data were also linked to the Registry
of Total Population and Population Changes for assessment
of vital status (data not available in Austria). Causes of
death were coded according to Eurostat European shortlist
for causes of death [22] and were obtained by linkage to
National Cause of Death Registry in each country.
Statistical methods
Hazard ratios and 95 % confidence intervals (95 % CI) for
increased height were analyzed with Cox proportional
hazards regression with attained age as the time scale.
Participants were followed from date of health examination
until date of cancer diagnosis or death of cancer, or until
censoring at the date of death from any cause, emigration,
or end of follow-up (for analysis of cancer: 31 December
2003 in Austria, 2005 in Norway, and 2006 in Sweden; for
cancer death: 31 December 2003 in Austria, and 2004 in
Norway and Sweden), whichever occurred first.
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The Cox models were adjusted for ten categories of date
of birth and ten categories of age at health examination,
and stratified for sub-cohort within the model. The pro-
portional hazards assumption was tested using Schoenfeld
residuals and found valid for this model. For total cancer
and cancer death, we calculated hazard ratios (HRs) in
categories of height. For total cancer and cancer death and
also for specific sites, we calculated HRs using height as a
continuos variable for 5 cm increment in height.
Effect modification by BMI, smoking and birth cohort
Body mass index (BMI; weight/height2 (kg/m2)) was
divided into categories as defined by WHO (\25, 25 to
\30, 30 kg/m2 and above) [23], and smoking was classi-
fied as never-smoker, ex-smoker, and smoker. We tested
for multiplicative interaction between categories of BMI or
smoking, and 5 cm increment in height, using likelihood
ratio test for total cancer and for each site. Since we tested
for interaction for each site, around 20 tests of multipli-
cative interactions were performed for each sex and each
exposure, and thus, we adjusted the significance level for
multiple testing using the Holm–Bonferroni correction
[24]. For those cancer sites where interaction was found,
we further investigated this by calculating HRs separately
for each strata of BMI or smoking.
We specifically examined potential effect modification
using a separate model with only subjects from Austria and
Norway born before 31 December 1945, since participants
in these countries may have been affected by dietary
restrictions [25]. Similar to above, the significance level
was adjusted with the Holm–Bonferroni correction.
Menopause
To investigate whether the association with height differed
by menopausal status, we calculated HRs of breast cancer
in groups according to age at diagnosis; assuming that
women before age 50 had not undergone menopause
(premenopausal), women aged 50–60 were equivocal
regarding menopausal status (perimenopausal) and that
women above age 60 years had undergone menopause
(postmenopausal).
Smoking-related cancers
Smoking-related cancers were defined according to defi-
nition by International Agency for Research on Cancer and
include cancer of the cervix, colorectum, kidney, liver/
intrahepatic bile ducts, larynx/trachea/bronchus/lung, lip/
oral cavity/pharynx, esophagus, pancreas, stomach, blad-
der, and bone marrow (acute and chronic myeloid leuke-
mia) [26]. All remaining cancers except those in the
category ‘‘Other cancers’’ were defined as not smoking-
related cancers. We calculated HRs for height in current
and never smokers in not smoking-related and smoking-
related cancers.
All statistical tests were two-sided, and p values lower
than 0.05 were considered statistically significant. Cal-
culations were performed with STATA MP/2 version
11.2.
Results
The pooled study cohort consisted of 297,156 women and
288,772 men, in total 585,928 participants with a mean age
at health examination of 43.1 years (SD = 11.0), and mean
year of birth 1949 for women and 1948 for men. Mean
follow-up time was 12.7 years (SD = 7.2) and mean
height at health examination was 164.3 cm (SD = 6.3) in
women and 177.3 cm (SD = 6.9) in men, Table 1. During
follow-up, 17,549 women and 21,313 men were diagnosed
with cancer and 5,431 women and 8,116 men died of
cancer. Out of the 6,161 women diagnosed with breast
cancer, 1,855 were diagnosed before age 50 (premeno-
pausal), 2,173 were diagnosed between age 50 and 60
(perimenopausal), and 2,133 were diagnosed after age 60
(postmenopausal). Out of the 1,014 women that died of
breast cancer, 432 were diagnosed before age 50, 253 were
diagnosed between age 50 and 60, and 329 were diagnosed
after age 60. Data on BMI and smoking were complete for
over 99 % of participants.
Study participants with short stature had a higher BMI
than taller participants; 16 % of women below 160 cm
were obese (BMI [ 30 kg/m2) versus 7 % of women
above 175 cm, and 12 % of men below 170 cm were obese
versus 9 % of men above 185 cm, Table 2. There was a
somewhat higher proportion of smokers among tall
women: 29 % of women above 175 cm versus 25 % of
women below 160 cm. In men, the opposite pattern was
seen: 30 % of men above 185 cm versus 35 % of men
below 170 cm.
Risk of cancer and cancer death in height categories
Increasing height was associated with an increased risk of
cancer in both women and men: HR 1.22 (95 % CI
1.13–1.22) for women of 175 cm and above compared to
women of 160–165 cm, p-trend \ 0.001, and HR 1.15
(95 % CI 1.09–1.15) for men of 185 cm and above com-
pared to men of 170–175 cm, p-trend \ 0.001, Fig. 1a.
Increasing height was associated with an increased risk of
cancer death in women and men: HR 1.09 (95 % CI
0.92–1.28) for women of 175 cm and above compared to
women of 160–165 cm, p-trend = 0.004, and HR 1.10
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(95 % CI 1.01–1.19) for men of 185 cm and above com-
pared to men of 170–175 cm, p-trend = 0.0035, Fig. 1b.
Specific cancer sites
Increasing height (per 5 cm) was associated with an
increased risk for total cancer in women, HR 1.07 (95 %
CI 1.06–1.09), and in men, HR 1.04 (95 % CI 1.03–1.06),
as well as an increased risk for 8 out of 21 cancer sites in
women and 9 out of 19 cancer sites in men, Fig. 2a, b. In
both sexes, the highest HR was seen for malignant mela-
noma; in women, HR 1.17 (95 % CI 1.11–1.24), and in
men, HR 1.12 (95 % CI 1.08–1.19). Height was not
associated with a decreased risk of any cancer in women
but was associated with decreased risk of gastric cancer in
men, HR 0.92 (95 % CI 0.87–0.97).
Death from cancer at specific sites
Increasing height (per 5 cm) was associated with an increased
risk for total cancer death in women, HR 1.03 (95 % CI
1.01–1.06), and in men, HR 1.03 (95 % CI 1.01–1.05), as well
as an increased risk of death from 2 out of 17 cancer sites in
women and 2 out of 14 cancer sites in men, Fig. 3a, b. In
women, the highest HR was seen for death of breast cancer,
HR 1.10 (95 % CI 1.04–1.16), and in men the highest HR was
seen for death of renal cell carcinoma, HR 1.18 (95 % CI
1.17–1.30). Height was not associated with a decreased risk of
death from any cancer in women but a decreased risk of dying
of gastric cancer in men, HR 0.92 (95 % CI 0.87–0.97).
After adjusting the p values for multiple testing, we
found an interaction between BMI and height for total
cancer in men (p \ 0.001), but no interaction between
height and smoking. In subsequent analysis of categories
of BMI, HRs for total cancer (per 5 cm increment) was
slightly higher in men that were overweight or obese; HR
1.06 (95 % CI 1.05–1.08) for BMI 25–30 and HR 1.07
(95 % CI 1.03–1.11) for BMI [ 30, as compared to HR
1.02 (95 % CI 1.01–1.04) for BMI \ 25. We found no
effect modification among those subjects born before 31
December 1945 in Austria and Norway that may have been
affected by nutritional restrictions during World War II,
after adjustment for multiple testing.
There was an association between height and risk of
breast cancer in postmenopausal women (age [ 60), HRs
(per 5 cm increment) was 1.11 (95 % CI 1.07–1.15) for
incident breast cancer and HR 1.10 (95 % CI 1.00–1.21)
for breast cancer death. There were no associations with
breast cancer in premenopausal women (age \ 50); HR
0.98 (95 % CI 0.94–1.02), or breast cancer death, HR 1.02
(95 % CI 0.94–1.11).
There were no significant differences in height-associ-
ated HRs for total cancer in non-smoking-related cancersT
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and smoking-related cancers in women, Fig. 4. The height-
associated HR for total cancer was higher in non-smoking-
related cancers than in smoking-related cancers in male
smokers; HR 1.10 (95 % CI 1.07–1.13) versus HR 1.02
(95 % CI 1.00–1.04).
Discussion
In this population-based study with more than 38,800
cancer cases and 13,500 cancer deaths, height was asso-
ciated with an increased risk of cancer incidence and death
for all sites combined. The highest height-related HR for
cancer incidence was found for malignant melanoma in
both women and men. For shared-site cancers, height was
positively associated with risk in both women and men for
lymphohematopoietic malignancies, colon and rectal
cancer, and non-melanoma and melanoma skin cancer. For
thyroid cancer, the association was restricted to women and
for renal cell carcinoma to men. The highest HR for cancer
death was observed for breast cancer in postmenopausal
women and renal cell carcinoma in men. For shared-site
cancers, height was positively associated with death of
colon cancer in women, and for men the association was of
border line significance. Associations to death of lympho-
hemapoietic malignancies and renal cell carcinoma were
restricted to men.
Our study has several strengths, it was large and popu-
lation-based, it included both cancer diagnosis and death
from different cancers, height was measured at health
examination, and the end points of cancer diagnoses were
obtained through linkages with national cancer registers
with almost complete capture of cancer cases [19–21].
However, we did not have information on potential
Table 2 Distribution of overweight and smoking in height categories in the Me-Can cohort
BMI Smoking
Below 25* 25 to \30 30 and above Never-smoker Former smoker Current smoker
Women N (%) N (%) N (%) N (%) N (%) N (%)
175 cm and above 10,540 (71) 3,342 (22) 1,035 (7) 6,955 (47) 3,569 (24) 4,329 (29)
170 to \175 cm 32,119 (69) 10,680 (23) 3,481 (8) 22,065 (48) 10,547 (23) 13,461 (29)
165 to \170 cm 55,799 (65) 21,582 (25) 7,843 (9) 42,247 (50) 18,082 (21) 24,459 (29)
160 to \165 cm 52,757 (61) 24,428 (28) 9,899 (11) 45,943 (53) 16,134 (19) 24,511 (28)
Below 160 cm 33,380 (53) 19,964 (31) 10,197 (16) 38,286 (60) 9,062 (14) 15,773 (25)
Men
185 cm and above 21,243 (51) 16,574 (40) 3,591 (9) 17,583 (42) 11,051 (27) 12,522 (30)
180 to \185 cm 32,646 (49) 28,445 (42) 5,902 (9) 27,623 (41) 17,351 (26) 21,627 (32)
175 to \180 cm 39,561 (48) 34,940 (43) 7,684 (9) 32,953 (40) 20,738 (25) 28,014 (34)
170 to \175 cm 28,032 (45) 27,777 (45) 6,536 (10) 25,562 (41) 14,684 (24) 21,741 (35)
Below 170 cm 15,481 (43) 15,978 (45) 4,305 (12) 15,268 (43) 7,841 (22) 12,467 (35)
* BMI in WHO categories
Fig. 1 Risk of total cancer (a) and cancer death (b) by height category for women and men. HRs are adjusted for date of birth and age at health
examination, and stratified for sub-cohort within the model
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confounders for female cancers, i.e., reproductive factors.
Also, we did not have information on socioeconomic sta-
tus, which might affect both cancer incidence and survival
[27]. However, in previous large studies, adjustment for
these factors did not affect risk estimates for the association
between height and cancer [2, 13, 14].
In our study, as well as in four previous large studies
on height and risk of all-sites cancer, height has showed
positive association to risk of cancers of the colon,
breast, and ovary in women [2, 13–15]. Our finding of
positive associations for thyroid cancer and malignant
melanoma in women has been reported in three out of
these four studies. For men, our finding of positive
associations for cancers of the colon, rectum, and
prostate are consistent with the only large previous study
on all-sites cancer that included both women and men, a
Korean cohort study of 9,400 female and 23,700 male
cancer cases [13]. Our finding of positive associations for
kidney and testicular cancer, and malignant melanoma,
are not consistent with the Korean study but are in
accordance with several large studies on height and
separate cancer sites [7, 8, 11].
In our study, height-associated HR for total cancer was
higher in not smoking-related cancers than in smoking-
related cancers in male smokers, similar to the finding in
women in the Million Women Study, a population-based
study including over 97,300 cancer cases [2]. For women
in our study, the risk estimates pointed in the same
Fig. 2 Risk of cancer by 5 cm increment in height for women (a) and men (b). HRs are adjusted for date of birth and age at health examination,
and stratified for sub-cohort within the model
Fig. 3 Risk of cancer death by 5 cm increment in height for women (a), and men (b). HRs are adjusted for date of birth, age at health
examination and stratified for sub-cohort within the model
156 Cancer Causes Control (2014) 25:151–159
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direction as in men, but they were not significant, possibly
due to limited number of cancer cases among female
smokers.
For cancer death, our findings of positive associations
between height and risk of death of breast and colon cancer
in women and lymphohematopoietic malignancies and
renal cell carcinoma in men are in line with a study on
height and the risk of cause-specific death that included
over one million individuals and over 47,000 cancer deaths
[16], with the exception of renal cell carcinoma which was
not included in this study. There has, to our knowledge,
been no large study on height and risk of death of kidney
cancer or renal cell carcinoma.
Our finding of an inverse association for height and risk
of diagnosis and death of gastric cancer in men was not
seen in the Korean all-sites cancer study which included
8,777 male cases of gastric cancer [13] but is in accordance
with the above-mentioned study on height and risk of
cause-specific death which included over 2,040 cases of
gastric cancer [16]. Although the study on mortality did not
analyze men and women separately but instead adjusted for
sex [16], this result is still likely representative for men
since the incidence of gastric cancer is twice as high in men
as in women [28]. The most important risk factor for
gastric cancer is infection with Helicobacter pylori (H.
pylori) [28], and as such exposure has been associated with
poor growth in children [29], this infection might explain
the inverse association between height and gastric cancer
seen in our study.
In our study, the highest HRs for height and risk of
cancer was for malignant melanoma in both women and
men. For women, two other studies on all-sites cancer have
also shown highest relative risks for malignant melanoma
[2, 14], while the all-sites cancer study that included both
women and men did not report results for malignant mel-
anoma separately from other skin cancers [13]. In the
present study, height was associated with a non-significant
increase in risk of death from malignant melanoma in both
men and women, and it was the cancer site associated with
the highest relative risk of cancer death in women and men
combined in the study on height and risk of cause-specific
death which included 679 deaths from malignant mela-
noma [16]. Possible explanations for this association are
increased skin surface or higher naevi count in taller
individuals, or differences in distribution of other risk
factors such as sun exposure [30]. However, adjusting for
physical appearance and sun exposure-related factors
associated with risk of melanoma did not affect the risk
estimates for height and risk in one pooled analysis of
2,083 female cases of malignant melanoma [10].
The incidence of many cancers that occur in both sexes
is higher in men than in women. In our study, this was true
for colon and rectal cancer and malignant melanoma (data
not shown), even after adjustment for smoking status and
BMI. Interestingly, one recent study that included 3,466
cases of cancer at shared sites as well as information on
several medical and lifestyle risk factors reported that over
30 % of this difference in total cancer risk could be
attributed to differences in height [31].
Adult height is determined to a large part by genetic
factors, but also by nutrition during childhood and ado-
lescence, mediated by factors in the growth hormone/
insulin-like growth factor axis, and other factors such as
living conditions and serious disease in childhood [32, 33].
Circulating levels of IGF-1 in adulthood are associated
with height in men and inconsistently also in women
[34, 35] and IGF-1 has consistently been associated with
increased risk of cancer of the breast, prostate, and colo-
rectum [35–38].
There are genes that are related both to increased height
and to oncogenic pathways such as c-Myc, p53, and
SMAD3, which are related to increased risk of cancer
tumorigenesis [39]. Also, height-related SNPs have been
associated with risk of testicular cancer [40]. The associ-
ation between height and cancer might also be influenced
by differences in other risk factors for cancer such as
smoking and obesity across the height categories. How-
ever, in previous studies, tall subjects tended to smoke less
and to have lower BMI [2, 13], two factors that are asso-
ciated with decreased risk of cancer. In our study, tall
Fig. 4 Risk of cancer by 5 cm increment in height for smoking-related and non-smoking-related cancers, in smokers and never smokers, for
women (a) and men (b). HRs are adjusted for date of birth and age at health examination, and stratified for sub-cohort within the model
Cancer Causes Control (2014) 25:151–159 157
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subjects had lower BMI, whereas tall women smoked more
and tall men smoked less than shorter individuals. Since
there were no significant interactions between height and
smoking status and risk of cancer in women, we do not
believe that the slightly higher proportion of smokers in tall
women can explain their increased risk of cancer.
Our study is, to the best of our knowledge, the first to
analyze height in relation to incidence and death of all-sites
cancer in the same cohort. For cancer with short overall
survival, the estimates of incidence and mortality are
expected to concur. In our study, this is mainly evident for
the inverse association between height and risk of diag-
nosis and death of gastric cancer in men. For cancers with
longer overall survival, such as cancer of the breast and
colon in women in our study, the association between
height and risk of cancer death might also to some part
indicate an association to more aggressive disease at
diagnosis or to progression. However, mortality in cancer is
strongly influenced by stage of disease at diagnosis and
treatment, factors that we were unable to control for in the
present study.
Conclusion
Our data from a large prospective pooled European cohort
study provide further evidence that height is associated
with increased risk of cancer and cancer death, indicating
that factors related to height such as genetic and hormonal
factors stimulate both cancer development and progression.
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